Vyome Bio's acne drug VB 1953 gets USFDA nod
Advertisement
Mumbai: Bio-pharmaceutical company Vyome Biosciences said the US Food and Drug Administration (USFDA) has cleared its investigational new drug (IND) to treat moderate-to-severe acne.
"We have received USFDA acceptance of Investigational New Drug application in the US for our lead product VB 1953 to treat moderate-to-severe acne. We plan to start Phase-I clinical trials very soon," a company statement said here.
"With US FDA accepting our first IND application for the lead program VB 1953, we have become a clinical stage company in US, which is an important value inflection milestone for us.
"This should pave way for further filings with the USFDA in future. VB 1953 is a first-in-class new product in Acne therapy for addressing one of the very important and a large unmet need," Vyome CEO N Venkat said.
"We have received USFDA acceptance of Investigational New Drug application in the US for our lead product VB 1953 to treat moderate-to-severe acne. We plan to start Phase-I clinical trials very soon," a company statement said here.
"With US FDA accepting our first IND application for the lead program VB 1953, we have become a clinical stage company in US, which is an important value inflection milestone for us.
"This should pave way for further filings with the USFDA in future. VB 1953 is a first-in-class new product in Acne therapy for addressing one of the very important and a large unmet need," Vyome CEO N Venkat said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.